This represents the first comprehensive evaluation of the role and clinical significance of YTHDF1 in colorectal CSCs and associated chemoresistance, and our findings position YTHDF1 as a promising therapeutic target to overcome chemoresistance associated with CSCs and improve treatment outcomes in CRC. This evidence concerns the gene YTHDF1 and colorectal carcinoma.